▶주메뉴 바로가기
▶본문 바로가기
Kolmar Korea said Thursday it had developed a new antiaging ingredient called Tocopherol-Oxalate-Tocopherol, or TOT, through joint research with a team led by Lee Dong-won at Jeonbuk National University. The research was selected as the cover article for the April 2026 issue of Molecules, an SCI-indexed international journal. TOT is a targeted antiaging material that combines two vitamin E molecules — known for their antioxidant properties — with a special binding agent called peroxalate. The in
Daewoong Pharmaceutical said Thursday it had acquired technology assets and related rights from Turn Biotechnologies through an auction bid, marking a major step into therapies targeting aging-related diseases. At the center of the acquisition is Turn Biotechnologies’ ERA platform, a partial reprogramming technology that uses mRNA-delivered reprogramming factors to restore aged cells to a younger and healthier state while preserving their original cellular identity. Unlike full reprogramming app
Samsung Bioepis said Wednesday it has launched autoimmune disease treatment SB17 in partnership with Nipro Corporation, marking the company’s first product launch in Japan and its full-scale entry into the market. SB17 is a biosimilar referencing Stelara and is used to treat immune-mediated diseases, including plaque psoriasis and psoriatic arthritis. The drug works by inhibiting interleukin-12 and interleukin-23, proteins linked to abnormal immune responses. Samsung Bioepis signed a strategic p
Lotte Biologics said Monday it signed a contract manufacturing agreement with UK biotech firm Ottimo Pharma for antibody drugs, expanding the two companies' existing partnership. Under the agreement, Lotte Biologics will produce the active pharmaceutical ingredient for Jankistomig, Ottimo Pharma’s biparatopic antibody candidate, at its Syracuse Bio Campus in New York. The deal builds on an antibody development agreement signed in June last year and reflects Ottimo Pharma’s continued confidence i
With Eli Lilly’s diabetes and obesity treatment Mounjaro overtaking MSD’s cancer therapy Keytruda as the world’s top-selling drug in the first quarter, Korean drugmakers are focusing on developing monthly obesity shots that involve less frequent injections. Mounjaro and Novo Nordisk’s diabetes and obesity treatment Wegovy currently require weekly injections. Samsung Epis Holdings’ two subsidiaries — biopharmaceutical developer Samsung Bioepis and biotechnology platform developer Epis NexLab — te
ST Pharm said Friday it joined the United Nations Global Compact, the world’s largest voluntary corporate sustainability initiative, as part of efforts to strengthen its global ESG management. Launched at the UN headquarters in 2000, the UNGC is a global corporate sustainability initiative involving more than 20,000 companies and organizations across over 160 countries working toward Sustainable Development Goals. Following the membership, the company plans to annually disclose a Communication o
Merck Life Science and GC Biopharma have signed a strategic memorandum of understanding to expand cooperation in biopharmaceutical development, good manufacturing practice production processes and technical collaboration, the companies said Thursday. Under the agreement, signed in Seoul on Wednesday, the two companies will work to strengthen supply stability and manufacturing competitiveness for GC Biopharma’s key therapies by establishing a more responsive production and supply system. Merck sa
Celltrion said Tuesday it acquired French health care company Gifrer as the Korean biopharmaceutical firm expands its European business to include generics and over-the-counter products. Gifrer operates more than 9,000 pharmacy sales channels and supply networks covering about 800 hospitals across France. The company sells over 140 OTC medicines, health supplements and consumer health care products, including saline solutions, teeth-whitening products, and infant care items with strong local mar
Daewoong Pharmaceutical said Friday it signed a strategic partnership agreement with TionLab Therapeutics to jointly develop and commercialize long-acting monthly semaglutide injectable to the global market. The agreement is characterized as an open innovation model, combining the capabilities of a bio startup and a leading pharmaceutical. With TionLab’s long-acting drug transmission platform technologies and Daewoong’s expertise in development and commercialization, both parties aim to secure a
Celltrion said Friday that Zymfentra, the world’s only subcutaneous formulation of infliximab, saw record-breaking prescription volume in the first quarter of this year. Not only did the volume skyrocket 185 percent year-on-year, but also outpaced the entirety of last year’s first-half results, signaling a strong growth trajectory. This stems from the “3P strategy” that Celltrion’s US subsidiary adopted since Zymfentra’s release, which efocuses on providers, payers, and patients. Providers, or d
Chipotle bets on Korea for first bite of Asia
Samsung vs. LG battle for AI cooling heats up
Musinsa posts record earnings on offline, global expansion
One purchase every 0.9 second: Olive Young foreign sales top W1tr
Samsung, SK hynix tax payments surge 167% on chip boom
SK Chemicals eyes European can-coating market
Sept. 2, 2026
May 21, 2026
May 21, 2026
May 20, 2026
May 18, 2026
May 16, 2026
May 15, 2026
May 14, 2026
May 12, 2026
May 8, 2026
May 8, 2026
